These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 24579907)

  • 1. Monitoring the efficacy of once-weekly teriparatide. Are bone turnover markers useful in predicting fracture risk?
    Anagnostis P; Karras SN; Goulis DG
    Curr Med Res Opin; 2014 Jun; 30(6):1177-8. PubMed ID: 24579907
    [No Abstract]   [Full Text] [Related]  

  • 2. Changes in bone mineral density, bone turnover markers, and vertebral fracture risk reduction with once weekly teriparatide.
    Tanaka S; Kuroda T; Sugimoto T; Nakamura T; Shiraki M
    Curr Med Res Opin; 2014 May; 30(5):931-6. PubMed ID: 24392946
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Author's response to letter to the editor.
    Tanaka S; Kuroda T; Sugimoto T; Nakamura T; Shiraki M
    Curr Med Res Opin; 2014 Aug; 30(8):1627-8. PubMed ID: 24730639
    [No Abstract]   [Full Text] [Related]  

  • 4. Vertebral fracture risk after once-weekly teriparatide injections: follow-up study of Teriparatide Once-Weekly Efficacy Research (TOWER) trial.
    Sugimoto T; Shiraki M; Nakano T; Kishimoto H; Ito M; Fukunaga M; Hagino H; Sone T; Kuroda T; Nakamura T
    Curr Med Res Opin; 2013 Mar; 29(3):195-203. PubMed ID: 23259702
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Once-weekly teriparatide treatment on osteoporosis].
    Nakano T
    Clin Calcium; 2014 Jan; 24(1):100-5. PubMed ID: 24369286
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Monitoring bone turnover markers during treatment with the anabolic agent teriparatide; in particular, treatment using daily and weekly subucutaneous injections].
    Miyauchi A
    Clin Calcium; 2012 Mar; 22(3):387-98. PubMed ID: 22370306
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment responses with once-weekly teriparatide therapy for osteoporosis.
    Shiraki M; Ueda S; Sugimoto T; Kuroda T; Nakamura T
    Osteoporos Int; 2016 Oct; 27(10):3057-62. PubMed ID: 27234671
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Evidence in the treatment of osteoporosis using weekly teriparatide injections].
    Nakamura Y
    Clin Calcium; 2012 Mar; 22(3):407-13. PubMed ID: 22370308
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized Teriparatide [human parathyroid hormone (PTH) 1-34] Once-Weekly Efficacy Research (TOWER) trial for examining the reduction in new vertebral fractures in subjects with primary osteoporosis and high fracture risk.
    Nakamura T; Sugimoto T; Nakano T; Kishimoto H; Ito M; Fukunaga M; Hagino H; Sone T; Yoshikawa H; Nishizawa Y; Fujita T; Shiraki M
    J Clin Endocrinol Metab; 2012 Sep; 97(9):3097-106. PubMed ID: 22723322
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Relationship of pharmacokinetics, changes of bone turnover markers and BMD/fractures efficacy during treatment with anabolic agents;Teriparatide daily and once weekly subcutaneous injections.].
    Miyauchi A
    Clin Calcium; 2016; 26(11):1583-1595. PubMed ID: 27777391
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Once-Weekly Injection of Low-Dose Teriparatide (28.2 μg) Reduced the Risk of Vertebral Fracture in Patients with Primary Osteoporosis.
    Fujita T; Fukunaga M; Itabashi A; Tsutani K; Nakamura T
    Calcif Tissue Int; 2014 Feb; 94(2):170-5. PubMed ID: 23963633
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Once-weekly teriparatide in hemodialysis patients with hypoparathyroidism and low bone mass: a prospective study.
    Sumida K; Ubara Y; Hoshino J; Mise K; Hayami N; Suwabe T; Kawada M; Imafuku A; Hiramatsu R; Hasegawa E; Yamanouchi M; Sawa N; Takaichi K
    Osteoporos Int; 2016 Apr; 27(4):1441-1450. PubMed ID: 26525045
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Osteoporosis Management Following Teriparatide Therapy For Vertebral Fractures: Are Patients On Correct Maintenance Therapy?
    O'Connor MB; Bond U; Yousif T
    Ir Med J; 2018 Mar; 111(3):724. PubMed ID: 30376242
    [No Abstract]   [Full Text] [Related]  

  • 14. [Therapeutic agents for disorders of bone and calcium metabolism--Teriparatide, parathyroid hormone (1-34) as a daily subcutaneous injection].
    Hashimoto Y; Wakayama N; Miyauchi A
    Clin Calcium; 2007 Jan; 17(1):48-55. PubMed ID: 17211093
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 24-Month Open-Label Teriparatide Once-Weekly Efficacy Research Trial Examining Bone Mineral Density in Subjects with Primary Osteoporosis and High Fracture Risk.
    Sugimoto T; Shiraki M; Fukunaga M; Hagino H; Sone T; Nakano T; Kishimoto H; Ito M; Yoshikawa H; Kishida M; Irie C; Nakamura T
    Adv Ther; 2017 Jul; 34(7):1727-1740. PubMed ID: 28631217
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of the effects of once-weekly and once-daily rhPTH (1-34) injections on promoting fracture healing in rodents.
    Zhang W; Zhu J; Ma T; Liu C; Hai B; Du G; Wang H; Li N; Leng H; Xu Y; Song C
    J Orthop Res; 2018 Apr; 36(4):1145-1152. PubMed ID: 28960481
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Change in lumbar spine BMD and vertebral fracture risk reduction in teriparatide-treated postmenopausal women with osteoporosis.
    Chen P; Miller PD; Delmas PD; Misurski DA; Krege JH
    J Bone Miner Res; 2006 Nov; 21(11):1785-90. PubMed ID: 17002571
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Effects of parathyroid hormone (teriparatide) on bone quality in osteoporosis].
    Saito M; Marumo K
    Clin Calcium; 2012 Mar; 22(3):343-55. PubMed ID: 22370301
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Updates on Lifestyle-Related Diseases and Bone Metabolism. Teriparatide for osteoporosis associated with lifestyle-related diseases].
    Fukumoto S
    Clin Calcium; 2014 Nov; 24(11):1701-5. PubMed ID: 25355155
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Osteoporosis in men: its pathophysiology and the role of teriparatide in its treatment.
    Gagnon C; Li V; Ebeling PR
    Clin Interv Aging; 2008; 3(4):635-45. PubMed ID: 19281056
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.